Study Of Safety, Blood Levels, And Brain Receptor Occupancy Of GSK163090 Using PET Imaging In Healthy Males

• Status: Completed
• Trial end date: 2007-12-01
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this study is to look at how much of a new drug, GSK163090, binds to proteins in the brain and how much stays in the blood over a range of different doses. This study will use a medical imaging technique called Positron Emission Tomography (PET) which uses an imaging agent called [11C]-WAY100635.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: GlaxoSmithKline

Criteria

Inclusion Criteria:

• Healthy male subjects, aged 18-45 years Body weight > 50 kg

• Non-Smoker

• Normal ECG, heart rate and blood pressure

Exclusion Criteria:

• History of any cardiac disease

• History of regular alcohol consumption averaging >14 drinks/week

• Current or recent gastrointestinal disease; History of psychiatric illness including any history of suicidal attempts

• Positive for Hepatitis B and C, and HIV.

• History of drug abuse.

• Exposure to research and/or medical protocol involving nuclear medicine, PET or radiological investigations with significant radiation burden

• Family history of cancer (one or more first-degree relative diagnosed before the age of 55).

• Suffers from claustrophobia

• History or presence of neurological or psychiatric conditions

• Presence of a cardiac pacemaker or other implanted electronic device or metal implants